Embedded Files
According to a recent report by Grand View Research, Inc., the global oncology-based in-vivo Contract Research Organization (CRO) market is projected to reach a market size of USD 2.37 billion by 2030. This market is expected to grow at a compound annual growth rate (CAGR) of 8.58% during the forecast period. Several key factors are driving this robust growth, including the increased outsourcing of research and development (R&D) activities by pharmaceutical companies, the rising demand for advanced and innovative medicines, and the wider implementation of internationally recognized standards by CROs.
In today’s highly competitive pharmaceutical landscape, companies are increasingly facing challenges such as patent expirations, the rapid expansion of generic drugs, and the introduction of biosimilar alternatives. These challenges are pushing many pharmaceutical firms to turn toward specialized CROs for support in preclinical and in-vivo research services. As a result, the oncology-based in-vivo CRO industry is positioned for substantial and lucrative growth in the coming years.
Additionally, ongoing technological advancements are opening up new opportunities in the market. Innovations such as mobile-enabled tools for participant recruitment and communication, web-based life science laboratories, and robotics-powered labs capable of conducting routine tests are revolutionizing how in-vivo studies are conducted. At the global scale, outsourcing in-vivo CRO services is becoming a strategic move for pharmaceutical sponsors aiming to enter new and emerging markets efficiently.
Major pharmaceutical corporations such as Pfizer and GlaxoSmithKline have increasingly engaged in partnerships with local Contract Manufacturing Organizations (CMOs) and CROs, especially in emerging economies. These collaborations have been instrumental in helping foreign firms achieve regulatory compliance, market penetration, and manufacturing goals more effectively in these regions.
Moreover, the market is expected to benefit from the increasing number of strategic mergers, acquisitions, and collaborations. For example, in January 2023, Bruker, a company specializing in analytical solutions, acquired Biogenesis, a Switzerland-based preclinical CRO. This acquisition was aimed at enhancing Bruker's capabilities in the preclinical research space and signifies the growing importance of consolidation and partnership within the industry to strengthen market position.
Get a preview of the latest developments in the Oncology Based In-vivo CRO Market? Download your FREE sample PDF copy today and explore key data and trends.
Oncology-Based In-vivo CRO Market Report Highlights:
• Solid Tumors Segment: In 2023, the solid tumors segment held the largest market share at 47.4%, driven by the increasing global incidence of cancer. International health organizations, such as the World Health Organization (WHO), are investing heavily in cancer research, focusing on identifying the causes, prevalence, and potential treatment strategies for various types of solid tumors. These initiatives are significantly boosting R&D activities and, in turn, demand for in-vivo CRO services.
• Patient-Derived Xenograft Model: Within the solid tumor-based models, the patient-derived xenograft (PDX) model is projected to record the fastest growth, with a CAGR of 9.21% over the forecast period. This growth is attributed to the model’s ability to mimic human tumor biology more accurately, thereby making it a valuable tool in preclinical oncology research.
• Regional Insights – North America: In 2023, North America accounted for the largest share of the global market at 49.97%, with the United States being the key contributor. The dominance of this region is largely due to increased funding for oncology research, along with the presence of established pharmaceutical and life sciences companies that continue to invest heavily in in-vivo research and development.
• Regional Outlook – Asia Pacific: The Asia Pacific region is expected to register the fastest CAGR over the forecast period. This rapid growth is supported by significant investments from developed countries in the Asia Pacific's healthcare infrastructure. Additionally, several regulatory bodies in the region have introduced reforms to align clinical trial evaluation standards with international benchmarks, thereby encouraging more global pharmaceutical companies to conduct trials in the region.
Oncology Based In-vivo CRO Market Segmentation
Grand View Research has segmented the global oncology based in-vivo CRO market based on indication, and region:
Oncology Based In-vivo CRO Indication Outlook (Revenue, USD Million, 2018 - 2030)
• Blood Cancer
o Syngeneic Model
o Patient-derived Xenograft
o Xenograft
• Solid Tumors
o Syngeneic Model
o Patient-derived Xenograft
o Xenograft
• Others
o Syngeneic Model
o Patient-derived Xenograft
o Xenograft
Oncology Based In-vivo CRO Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
o U.S.
o Canada
o Mexico
• Europe
o U.K.
o Germany
o France
o Italy
o Spain
o Denmark
o Sweden
o Norway
• Asia Pacific
o Japan
o China
o India
o Australia
o South Korea
o Thailand
• Latin America
o Brazil
o Argentina
• Middle East & Africa
o South Africa
o Saudi Arabia
o UAE
o Kuwait
List of Key Players in the Oncology Based In-vivo CRO Market
• Charles River Laboratory
• ICON Plc
• Thermo Fisher Scientific Inc.
• Eurofins Scientific
• Taconic Biosciences
• Crown Bioscience
• LabCorp
• WuXi AppTec
• EVOTEC
• The Jackson Laboratory
Order a free sample PDF of the Oncology Based In-vivo CRO Market Intelligence Study, published by Grand View Research.
Page updated
Google Sites
Report abuse